Stacy C. Dilzer
Clinical Pharmacology of Miami(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Peptidase Inhibition and Analysis, Antifungal resistance and susceptibility, Neuroendocrine Tumor Research Advances, Pancreatic function and diabetes
Most-Cited Works
- → Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet(2000)337 cited
- → Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects(2006)184 cited
- → Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans(2007)148 cited
- → Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma(2004)137 cited
- → Potential for Interactions between Caspofungin and Nelfinavir or Rifampin(2004)99 cited
- → Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment(2001)95 cited
- → Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers(2007)88 cited
- → Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations(2007)66 cited
- → The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin(2007)64 cited
- Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.(2009)